Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2018 - ResearchAndMarkets.com
Aug. 31, 2018
DUBLIN--(BUSINESS WIRE)--Aug 31, 2018--The "Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Progressive Multifocal Leukoencephalopathy - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Progressive Multifocal Leukoencephalopathy development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Progressive Multifocal Leukoencephalopathy Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Progressive Multifocal Leukoencephalopathy
4. Comparative Analysis
5. Products in Clinical StageProduct Description Research and Development Product Development Activities
6. Products in Pre-Clinical and Discovery StageProduct Description Research and Development Product Development Activities
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive ProductsProduct Description Research and Development Product Development Activities
Companies MentionedExcision BioTherapeutics Inc Neurimmune Holding AG Neuway Pharma GmbH Pomona Ricerca SRL Inhibikase Therapeutics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hgzjnz/progressive?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180831005418/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs ,Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/31/2018 01:46 PM/DISC: 08/31/2018 01:46 PM